Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
Philip C. Robinson, Duncan Richards, Helen Tanner, Marc Feldmann
Topics & Concepts
MedicineCytokineTumor necrosis factor alphaCoronavirus disease 2019 (COVID-19)PandemicCytokine stormDexamethasoneImmunologyInternal medicineDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesInflammasome and immune disordersLong-Term Effects of COVID-19